ERBB2 and cancer: Commercialized bio-radiopharmaceuticals and current compounds in pre-clinical and clinical testing all target antigens (CD20, CD19, HER2, EGFR, PSMA, etc.)that are highly expressed on cancer cells with low expression on healthy tissues [14].